Quick Answer
CERO THERAPEUTICS HOLDINGS, INC. reported Cash and Equivalents of $96.9 thousand for fiscal year 2023.
CERO THERAPEUTICS HOLDINGS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $96.9K | -79.6% |
| 2022 | $475.9K | -56.7% |
| 2021 | $1.10M | — |
| 2021 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.90M | — | -40.6% |
| June 30, 2025 | $3.20M | — | -37.3% |
| March 31, 2025 | $5.10M | — | +4185.2% |
| September 30, 2023 | $119.0K | — | -33.2% |
| March 31, 2023 | $178.1K | — | -62.6% |
| December 31, 2022 | $475.9K | — | — |
| September 30, 2021 | $0.00 | — | — |
| May 31, 2021 | $0.00 | — | — |
- CERO THERAPEUTICS HOLDINGS, INC. showed a decrease of -79.6% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from CERO THERAPEUTICS HOLDINGS, INC.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 2, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: